Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BIND Biosciences, Inc. Receives $2M NIST ATP Award to Develop a High-Throughput Platform for Targeted Nanoparticle Engineering

Abstract:
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing therapeutic targeted nanoparticles, announced today that it has received a three year $2,000,000 award from the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP) to further develop its platform for high-throughput formulation and selection of targeted nanoparticles.

BIND Biosciences, Inc. Receives $2M NIST ATP Award to Develop a High-Throughput Platform for Targeted Nanoparticle Engineering

Cambridge, MA | Posted on October 11th, 2007

"Given the extremely rigorous technical peer review involved in this competition, this award represents an important validation of BIND's technology platform," according to Dr. Stephen Zale, Vice President of Development at BIND and Principal Investigator of BIND's ATP project. He continued, "The ATP funding will accelerate industrialization of our high-throughput combinatorial platform for nanoparticle fabrication and screening that uniquely enables BIND to develop and manufacture targeted nanoparticle therapeutics optimized for a specific disease."

"We are delighted to have been selected by NIST for the ATP award and for their recognition of our platform's potential to create an entirely novel class of therapeutics based on optimally engineered targeted polymeric nanoparticles," said Glenn Batchelder, President and Chief Executive Officer of BIND. "We are fortunate to have Dr. Zale leading this program. Dr. Zale's two decades of pharmaceutical development experience includes a twelve year tenure at Alkermes where, as Vice President of Injectable Products, he helped build an extremely successful polymeric microparticle-based drug delivery platform which has led to the commercialization of important products such as Risperdal ConstaTM and VivitrolTM."

The NIST Advanced Technology Program selects the most promising early stage technologies with the potential to create fundamental paradigm shifts in their respective spaces. Of the hundreds of applicants for this year's ATP NIST program, less than ten percent were awarded contracts. ATP's early stage support has dramatically accelerated the development of many innovative technologies resulting in long term commercial success and delivering far reaching societal benefits.

####

About BIND Biosciences, Inc.
BIND Biosciences is a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles. The company’s product-platform leverages the convergence of polymeric biomaterials, nanoparticle engineering and combinatorial synthesis to uniquely enable BIND to design and optimize targeted nanoparticle therapeutics for specific indications. BIND’s technology concentrates drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects. The company’s platform is broadly applicable across therapeutic areas with the initial product development efforts focused in cancer and cardiovascular disease. The company anticipates initiating clinical trials for their first product in 2009.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Assistant Professor of Anesthesiology. Backed by leading venture capital firms, Flagship Ventures and Polaris Venture Partners, the company has licensed a large patent estate covering these technologies on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital – Harvard Medical School.

For more information, please click here

Contacts:
BIND Biosciences, Inc.
Glenn Batchelder, 617-491-3400
President and CEO

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Govt.-Legislation/Regulation/Funding/Policy

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

One step closer to a single-molecule device: Columbia Engineering researchers first to create a single-molecule diode -- the ultimate in miniaturization for electronic devices -- with potential for real-world applications May 25th, 2015

DNA Double Helix Does Double Duty in Assembling Arrays of Nanoparticles: Synthetic pieces of biological molecule form framework and glue for making nanoparticle clusters and arrays May 25th, 2015

Announcements

Physicists solve quantum tunneling mystery: ANU media release: An international team of scientists studying ultrafast physics have solved a mystery of quantum mechanics, and found that quantum tunneling is an instantaneous process May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

Controlled Release of Anticorrosive Materials in Spot by Nanocarriers May 27th, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

One step closer to a single-molecule device: Columbia Engineering researchers first to create a single-molecule diode -- the ultimate in miniaturization for electronic devices -- with potential for real-world applications May 25th, 2015

What makes cancer cells spread? New device offers clues May 19th, 2015

Researchers build new fermion microscope: Instrument freezes and images 1,000 individual fermionic atoms at once May 13th, 2015

International and U.S. Students and Teachers Headed to Toronto for 34th Annual International Space Development Conference®: Students competed in prestigious NSS-NASA Ames Space Settlement Design Contest May 9th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project